Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.36 |
| ▸ | IDH1 | O75874 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8039039 | 0.78 | GSK3B (0.39) | DRD2DRD3IDH1HTR2AHTR2C | |
| SCHEMBL15529909 | 0.75 | IDH1 (0.39) | DRD2IDH1HTR2AHTR2CHTR2B | |
| SCHEMBL483331 | 0.75 | HTR2A (0.37) | IDH1HTR2AHTR2CHTR2BGSK3B | |
| SCHEMBL18068274 | 0.74 | PDPK1 (0.38) | DRD2DRD3IDH1HTR2AHTR2C | |
| SCHEMBL18067769 | 0.74 | IDH1 (0.36) | DRD2DRD3IDH1HTR2AHTR2C | |
| SCHEMBL23583899 | 0.74 | DRD3 (0.38) | DRD2DRD3IDH1GSK3BCYP2D6 | |
| SCHEMBL29482177 | 0.74 | IDH1 (0.38) | MTNR1AIDH1 | |
| SCHEMBL29482176 | 0.74 | IDH1 (0.38) | MTNR1AIDH1 | |
| SCHEMBL31445834 | 0.74 | GRIN2B (0.48) | GRIN1GRIN2BCYP2D6 | |
| SCHEMBL19892039 | 0.73 | HTR2A (0.38) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | THE GENERAL HOSPITAL CORPORATION | 2016-10-13 | — | — | US | disclosed |
| US-9345739-B2 | Methods and compositions for the treatment of proteinuric diseases | THE GENERAL HOSPITAL CORPORATION (US) | 2016-05-24 | — | — | US | disclosed |
| EP-2730282-A1 | Methods and compositions for the treatment of proteinuric diseases | The General Hospital Corporation (US) | 2014-05-14 | — | — | EP | disclosed |
| US-20100297139-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | THE GENERAL HOSPITAL CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100297139-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | THE GENERAL HOSPITAL CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100048536-A1 | Novel Substituted Diaryl Azepine Derivatives as Integrin Ligands | GENESTE HERVE | 2010-02-25 | — | — | US | disclosed |
| US-20080221082-A1 | Ligands of Integrin Receptors | ABBOTT GMBH & CO. KG (DE) | 2008-09-11 | — | — | US | disclosed |
| US-7279468-B2 | Integrin ligands | ABBOTT GMBH & CO. KG (DE) | 2007-10-09 | — | — | US | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296592-A1 | Methods and Compositions for the Treatment of Proteinuric Diseases | ITGB3, PLAUR, PROC | DRD2 4797/4885DRD3 4395/4885MTNR1A 2866/4885 |
| US-20100048536-A1 | Novel Substituted Diaryl Azepine Derivatives as Integrin Ligands | ITGB3, ITGAL, ITGB4 | DRD2 680/4885DRD3 807/4885MTNR1A 1513/4885 |
| US-20100297139-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROTEINURIC DISEASES | ITGB3, PLAUR, PROC | DRD2 4797/4885DRD3 4395/4885MTNR1A 2866/4885 |
| US-20080221082-A1 | Ligands of Integrin Receptors | ITGB3, ITGAV, ITGA2B | DRD2 2641/4885DRD3 2048/4885MTNR1A 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.